MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

Molecular Pharmacology Fast Forward
First published on February 9, 2005; DOI: 10.1124/mol.105.011783

0026-895X/05/6705-1385-1387$20.00
Mol Pharmacol 67:1385-1387, 2005

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Related Article
Right arrow All Versions of this Article:
mol.105.011783v1
67/5/1385    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Linden, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Linden, J.
PERSPECTIVE

Adenosine in Tissue Protection and Tissue Regeneration

Joel Linden

Department of Medicine, University of Virginia, Charlottesville, Virginia

Adenosine promotes tissue protection and repair through four general modes of action: increased oxygen supply/demand ratio, preconditioning, anti-inflammatory effects, and stimulation of angiogenesis. A novel means by which adenosine stimulates angiogenesis is the topic of the article by Desai et al. in the April 2005 issue of Molecular Pharmacology. The report demonstrates that agonists of A2A adenosine receptors inhibit the release of the anti-angiogenic factor thrombospondin 1. Multiple cell types and all four adenosine receptors participate in these responses. Exploiting these effects of adenosine has great therapeutic potential.

Received February 3, 2005; accepted February 9, 2005

Address correspondence to: Dr. Joel Linden, Department of Medicine, University of Virginia, Charlottesville, VA 22908. E-mail: jlinden{at}virginia.edu




This article has been cited by other articles:


Home page
 FASEB J.Home page
M. L. Hart, M. Henn, D. Kohler, D. Kloor, M. Mittelbronn, I. C. Gorzolla, G. L. Stahl, and H. K. Eltzschig
Role of extracellular nucleotide phosphohydrolysis in intestinal ischemia-reperfusion injury
FASEB J, August 1, 2008; 22(8): 2784 - 2797.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
L. Tacchini, E. Gammella, C. De Ponti, S. Recalcati, and G. Cairo
Role of HIF-1 and NF-{kappa}B Transcription Factors in the Modulation of Transferrin Receptor by Inflammatory and Anti-inflammatory Signals
J. Biol. Chem., July 25, 2008; 283(30): 20674 - 20686.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
Z. Peng, P. Fernandez, T. Wilder, H. Yee, L. Chiriboga, E. S. L. Chan, and B. N. Cronstein
Ecto-5'-nucleotidase (CD73) -mediated extracellular adenosine production plays a critical role in hepatic fibrosis
FASEB J, July 1, 2008; 22(7): 2263 - 2272.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. C. Morote-Garcia, P. Rosenberger, J. Kuhlicke, and H. K. Eltzschig
HIF-1-dependent repression of adenosine kinase attenuates hypoxia-induced vascular leak
Blood, June 15, 2008; 111(12): 5571 - 5580.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
T. Eckle, M. Faigle, A. Grenz, S. Laucher, L. F. Thompson, and H. K. Eltzschig
A2B adenosine receptor dampens hypoxia-induced vascular leak
Blood, February 15, 2008; 111(4): 2024 - 2035.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
C. De Ponti, R. Carini, E. Alchera, M. P. Nitti, M. Locati, E. Albano, G. Cairo, and L. Tacchini
Adenosine A2a receptor-mediated, normoxic induction of HIF-1 through PKC and PI-3K-dependent pathways in macrophages
J. Leukoc. Biol., August 1, 2007; 82(2): 392 - 402.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
T. Eckle, T. Krahn, A. Grenz, D. Kohler, M. Mittelbronn, C. Ledent, M. A. Jacobson, H. Osswald, L. F. Thompson, K. Unertl, et al.
Cardioprotection by Ecto-5'-Nucleotidase (CD73) and A2B Adenosine Receptors
Circulation, March 27, 2007; 115(12): 1581 - 1590.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
Z. Aydin, A. J. van Zonneveld, J. W. de Fijter, and T. J. Rabelink
New horizons in prevention and treatment of ischaemic injury to kidney transplants
Nephrol. Dial. Transplant., February 1, 2007; 22(2): 342 - 346.
[Full Text] [PDF]

Home page
 J. Exp. Med.Home page
C. M. Lappas, Y.-J. Day, M. A. Marshall, V. H. Engelhard, and J. Linden
Adenosine A2A receptor activation reduces hepatic ischemia reperfusion injury by inhibiting CD1d-dependent NKT cell activation
J. Exp. Med., November 27, 2006; 203(12): 2639 - 2648.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
Z. Yang, Y.-J. Day, M.-C. Toufektsian, Y. Xu, S. I. Ramos, M. A. Marshall, B. A. French, and J. Linden
Myocardial Infarct-Sparing Effect of Adenosine A2A Receptor Activation Is due to Its Action on CD4+ T Lymphocytes
Circulation, November 7, 2006; 114(19): 2056 - 2064.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
O. Levy, M. Coughlin, B. N. Cronstein, R. M. Roy, A. Desai, and M. R. Wessels
The Adenosine System Selectively Inhibits TLR-Mediated TNF-{alpha} Production in the Human Newborn
J. Immunol., August 1, 2006; 177(3): 1956 - 1966.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
I. Gsandtner and M. Freissmuth
A Tail of Two Signals: The C Terminus of the A2A-Adenosine Receptor Recruits Alternative Signaling Pathways
Mol. Pharmacol., August 1, 2006; 70(2): 447 - 449.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2005 by the American Society for Pharmacology and Experimental Therapeutics